Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$167.33 USD

167.33
2,406,416

+3.32 (2.02%)

Updated May 24, 2024 11:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 249)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag

The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

Moderna (MRNA) closed at $154.61 in the latest trading session, marking a -1.22% move from the prior day.

Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Moderna (MRNA). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Disney, Marathon Petroleum, Moderna, Nucor and CenterPoint Energy

Disney, Marathon Petroleum, Moderna, Nucor and CenterPoint Energy are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Walt Disney, Marathon Petroleum & Moderna

Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Marathon Petroleum Corporation (MPC), and Moderna, Inc. (MRNA).

Mirati (MRTX) Down 16.1% Since Last Earnings Report: Can It Rebound?

Mirati (MRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moderna (MRNA) Gains But Lags Market: What You Should Know

Moderna (MRNA) closed at $148.80 in the latest trading session, marking a +1.28% move from the prior day.

Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

Smart Beta ETF report for RYH

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed the most recent trading day at $149.42, moving +0.84% from the previous trading session.

Moderna (MRNA) Gains But Lags Market: What You Should Know

Moderna (MRNA) closed at $151.78 in the latest trading session, marking a +1.46% move from the prior day.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants

Pfizer (PFE) and partner BioNTech receive FDA label expansion to use their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a single booster dose in young children under five years.

Moderna, Inc. (MRNA) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moderna (MRNA) Gains As Market Dips: What You Should Know

Moderna (MRNA) closed at $138.29 in the latest trading session, marking a +0.68% move from the prior day.

Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day

Six Flags and Equinox Gold have been highlighted as Zacks Bull and Bear of the Day.

Pfizer (PFE) or GSK: Who Will Get the First FDA Nod for RSV Jab?

An FDA advisory committee recommended approving Pfizer's (PFE) and GSK's respective RSV vaccines for older adults. Currently, there are no RSV vaccines anywhere in the world.

Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?

Style Box ETF report for SPGP

Moderna, Inc. (MRNA) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Moderna (MRNA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback

Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week.